CClinicalTrials.gg
RecruitingNCT06414785INFLAMAUpdated May 16, 2024

Characterization of Capsule Inflammation in Patients Exposed to Silicone Breast Implants

An observational study in Breast Implant; Complications and Breast Expansion Prosthesis, sponsored by Centre Hospitalier Universitaire de Besancon. Recruiting at 1 site in France. Open to female participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-05-16.

Sponsored by Centre Hospitalier Universitaire de Besancon · Observational

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 5 months later.
Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
100
Ages
18 Years to 99 Years
Sex
Female
01

Study summary

The use of breast implants, both in cosmetic and restorative surgery, is common. It is a device consisting of a silicone elastomer envelope and the container of which may be silicone gel or saline. They can be texturing carriers (roughness) on the surface of their envelope.

If silicone is considered inert and biocompatible, several phenomena should be noted:

  • Implant placement results in the formation of a periprosthetic capsule which is the product of the inflammatory reaction and will isolate it from adjacent breast tissue
  • The periprosthetic capsule and adjacent breast tissue are chronically exposed to implant silicone.
  • Silicone in implants, even intact, has been shown to diffuse through the shell into the periprosthetic compartment and adjacent breast tissue
  • There is a phenomenon of erosion of the surface of the implants, particularly textured, responsible for the release of silicone particles within the periprosthetic capsule
  • The rupture of the prosthetic envelope is a dreaded complication, due to the alteration of the aesthetic result and the possibility of leakage of silicone gel
  • Since 2016, macrotextured implants have been implicated in the occurrence of anaplastic large cell lymphoma associated with breast implants (LAC-AIM) The presence of silicone in contact with tissues seems to promote an inflammatory environment, and this phenomenon seems increased if the implant is textured.

Chronic inflammation induced by these devices can therefore have harmful consequences in the long term. INFLAMA study interested in the consequences of the presence of a silicone implant on local inflammatory phenomena within the periprosthetic capsule.

02

Conditions studied

  • Breast Implant; Complications
  • Breast Expansion Prosthesis

Browse trials for

Keywords

  • type of texturing of implants
  • periprosthetic capsule fragment
03

In context

Inflammation

3,439 studies on the registry are indexed under Inflammation; 629 are open to participants now.

This study's planned enrollment of 100 is close to the median of 95 across 895 observational studies indexed under Inflammation.

Browse Inflammation studies →

Lead sponsor

Centre Hospitalier Universitaire de Besancon is the lead sponsor of 439 studies on the registry; 97 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women Requiring a change of unilateral/bilateral breast implants or breast expansion prosthesis

Inclusion criteria

  • Women over the age of 18 years old
  • Requiring a change of unilateral/bilateral breast implants or breast expansion prosthesis for cosmetic surgery or breast reconstruction
  • Subject not objecting to the use of personal data and/or biological samples
  • Affiliation to or beneficiary of a French social security scheme.

Exclusion criteria

Exclusion Criteria:

  • Transgender men and patients
  • Pregnant women, and nursing mothers
  • Persons deprived of their liberty by a judicial or administrative decision;
  • Persons undergoing psychiatric care under duress;
  • Persons admitted to a health or social establishment for purposes other than research
  • Persons of full age who are subject to a legal protection measure or who cannot express their consent
  • Subject being in the period of exclusion from another study or foreseen by the "national volunteer file".
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No

Interventions

  • Otheranalysis of samples of periprosthetic capsules taken during breast implant change procedure

    characteristics of inflammation and the importance of silicone exposure (intact implant, implant rupture in serum or silicone) at the genomic molecular level, by analyzing the level of expression of genes related to the extracellular matrix and inflammation within a periprosthetic capsule fragment

06

What researchers measure

Primary outcomes

  1. characteristics of inflammation according to the importance of silicone exposure

    Verify the existence of a relationship between the characteristics of inflammation and the importance of silicone exposure (intact implant, implant rupture in serum or silicone) at the genomic molecular level, by analyzing the level of expression of genes related to the extracellular matrix and inflammation within a periprosthetic capsule fragment

    Time frame: immediately after surgery

Secondary outcomes

  1. characteristics of inflammation according to the type of texturing of implants

    Check the existence of a relationship between the characteristics of inflammation and the type of texturing of implants (smooth, micro textured or macro textured), on the genomic molecular level, by analyzing the level of expression of genes related to the extracellular matrix and inflammation within a periprosthetic capsule fragment.

    Time frame: immediately after surgery

  2. Characterize the inflammatory reaction within the periprosthetic capsule histologically, depending on the importance of silicone exposure.

    Time frame: immediately after surgery

  3. Characterize the inflammatory reaction within the periprosthetic capsule histologically, according to texturation.

    Time frame: immediately after surgery

  4. Identify a possible relationship between the characteristics of inflammation and the presence of a clinical shell.

    Time frame: immediately after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06414785
Lead sponsor
Centre Hospitalier Universitaire de Besancon
Collaborators
Institut de Science des Matériaux de Mulhouse IS2M, NOVOTEC labs (lyon)
Responsible party
Sponsor
First posted
May 16, 2024
Start date
May 3, 2024
Primary completion
May 31, 2025 (estimated)
Completion
May 31, 2025 (estimated)
Last update
May 16, 2024

Study contacts

Isabelle PLUVY, MD
Contact
i1pluvy@chu-besancon.fr
+33381218988
astrid pozet
Contact
apozet@chu-besancon.fr
Isabelle PLUVY
principal investigator · CHU de Besançon

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion